Terbutaline modulation of human allergic skin reactions

Stanislaus Ting*, Burton Zweiman, Robert Lavker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Terbutaline, a preferential beta2-adrenergic agonist, has been shown to inhibit allergen-induced histamine release in vitro. In contrast, orally administered therapeutic doses of terbutaline do not inhibit antigen-induced wheal and flare reactions. We studied the effects of local terbutaline on antigen-induced whealing response, histamine release, cellular inflammatory response, and ultramicroscopic mast cell changes in antigen-challenged skin sites in ragweed-sensitive subjects. Results showed that ragweed challenge significantly induced increased histamine release in all subjects. In contrast, no such histamine release was observed at sites challenged with antigen in the presence of terbutaline. Thus locally applied terbutaline in nontoxic doses modulates mediator release in certain allergic reactions.

Original languageEnglish (US)
Pages (from-to)437-441
Number of pages5
JournalThe Journal of allergy and clinical immunology
Volume71
Issue number5
DOIs
StatePublished - May 1983

Funding

Supported by National Institutes of Health grants A14Q1, A114332, and 5T AI 0703 1.

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Terbutaline modulation of human allergic skin reactions'. Together they form a unique fingerprint.

Cite this